Evidence map›Paper›PMID 23919589›Full record

ArticleDiabetes technology & therapeutics2013

A novel mathematical model detecting early individual changes of insulin resistance.

Claudia Eberle, Wulf Palinski, Christoph Ament

Abstract read
In one paragraph

Article in Diabetes technology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Claudia Eberle1 Department of Medicine, University of California San Diego , La Jolla, California.
Wulf Palinski
Christoph Ament
University of California San Diego · USTechnische Universität Ilmenau · DE

Funding

Fetal Determinants of AtherosclerosisR01HL067792 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PALINSKI, WULF · 2003 to 2006
$2.0M
Developmental immune programming and postnatal atherosclerosisR01HL089559 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PALINSKI, WULF · 2008 to 2011
$1.9M
NHLBI NIH HHS HL-067792NHLBI NIH HHS HL-089559
6 · The paper itself

Abstract

backgroundInsulin resistance (IR) and hyperinsulinemia as well as obesity play a key role in the metabolic syndrome (MetS), type 2 diabetes (T2D), and associated cardiovascular disease. Unfortunately, IR and hyperinsulinemia are often diagnosed late (i.e., when the MetS is already clinically evident). An earlier diagnosis of IR would be desirable to reduce its clinical consequences, in particular in view of the increasing prevalence of obesity and diabetes conditions. For this purpose, we developed a mathematical model capable of detecting early onset of IR through small variations of insulin sensitivity, glucose effectiveness, and first- or second-phase responses. MATERIALS AND

methodsMurine models provide controlled conditions to study various stages of IR. Various degrees of hypercholesterolemia, obesity, IR, and atherosclerosis were induced in low-density lipoprotein receptor-deficient mice by feeding them cholesterol- or sucrose-rich diets. IR was assessed by oral glucose tolerance tests. Controls included animals fed exclusively, or switched back to, regular chow. A nonlinear mathematical model of the order of 5 was developed by refining Bergman's "Minimal Model" and then applied to experimental data.

resultsDifferent metabolic constellations consistently corresponded to specific and close-meshed changes in model parameters. Reduced second-phase glucose sensitivity characterized an early impaired glucose tolerance. Later stages showed an increased first-phase glucose sensitivity compensating for decreased insulin sensitivity. Finally, T2D was associated with both first- and second-phase sensitivities close to zero.

conclusionsThe new mathematical model detected various insulin-sensitive or -resistant metabolic stages of IR. It can therefore be implemented for quantitative metabolic risk assessment and may be of therapeutic value by anticipating the start of therapeutic interventions.

Indexed as

Insulin ResistanceModels, TheoreticalAnimalsAtherosclerosisBlood GlucoseDiabetes Mellitus, Type 2Diabetic AngiopathiesDisease Models, AnimalEarly DiagnosisGlucose Tolerance TestMaleMetabolic SyndromeMiceObesityReceptors, LDLBlood GlucoseReceptors, LDL

Identifiers

PMID23919589
PMCPMC3781137
OpenAlexW2017253373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.